TransMedics Group, Inc.

TMDX Healthcare Medical Devices

TransMedics Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $605.5 million, up 37.1% from fiscal 2024. In the quarter to June 2026, revenue grew 20.7%, EPS fell 59.2%, free cash flow fell 87.6% and total debt rose 68.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

70.78 5.74 −7.50%
Market cap
$2.7B
P/E
16.0×
Fwd P/E
34.1×
Dividend yield
—
F-score
7/9
Altman Z
5.32
Beneish M
−1.32
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

7 7 4 3
ROE
32.48% 54.24% 45.22% 36.28%
ROA
10.60% 20.33% 15.13% 12.88%
ROIC
14.97% 13.65% 6.64% 5.62%
Return on Tangible Assets
10.84% 21.72% 19.34% 16.52%
Average Days of Receivables
52.01 50.81 52.08 56.86
Free Cash Flow per Share
3.54 3.93 4.40 2.29
Free Cash Flow
120.65 133.59 151.36 79.04
Other line items

Show all line items

Columns are period end dates